Pharmacotherapy options in rheumatoid arthritis

Area of Science:

• Rheumatology
• Pharmacology
• Immunology

Background:

• Rheumatoid arthritis (RA) management relies heavily on pharmacotherapy.
• Key drug classes include analgesics, NSAIDs, glucocorticoids, and disease-modifying antirheumatic drugs (DMARDs).
• Biologic agents are increasingly utilized for RA patients with inadequate response or intolerance to conventional DMARDs.

Purpose of the Study:

• To review current therapeutic strategies for rheumatoid arthritis.
• To outline the recommended sequence for initiating biologic agents in RA treatment.
• To compare the efficacy and safety profiles of various biologic therapies.

Main Methods:

• Literature review of current clinical practice guidelines for RA treatment.
• Analysis of data on the efficacy of different classes of antirheumatic drugs.
• Evaluation of treatment algorithms for initiating biologic therapies based on patient response.

Main Results:

• Traditional DMARDs like methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine are foundational treatments.
• Anti-TNF agents are the most common first-line biologic therapy, often in combination with methotrexate.
• Tocilizumab shows promise as a monotherapy, while rituximab, despite safety concerns, is effective but not typically a first-line biologic.
• Newer oral small molecule biologics like tofacitinib lack long-term data and are reserved for last-resort treatment.

Conclusions:

• The choice of biologic therapy in RA depends on patient response, tolerance, and safety profiles.
• Anti-TNF agents remain a primary biologic option, with other agents like tocilizumab and abatacept offering alternatives.
• Further long-term data is needed for newer oral small molecule therapies in RA management.